Scotland's MGB Bags More Funds To Tackle Antibiotic Resistance
Executive Summary
The Glasgow-based group has raised more cash to take its new class of anti-infective through Phase IIa trials for C diff-associated disease.
Topics
- Subjects
- Financing
- Clinical Trials
- Commercial
- StartUps and SMEs
- Therapy Areas
- Infectious Diseases
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC125787
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC125787
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.